Aftermath of the Human Genome Project: an era of struggle and discovery

The collaboration between the Human Genome Project and the Sanger Institute, spurred on by their contemporary- Celera Genomics, in the race to sequence the human genome, opened the door to a generation of research concerned with the study of the nucleic manual. Following this monumental achievement, the genomic era was born, heralding the development of gene therapy, personalized medicine, pharmacogenomics, and CRISPR/Cas9 gene-editing systems. These omic disciplines offer a wide range of applications in the treatment of disease and the betterment of the quality of human life. Their notability, however, manifests in the unique mix of sociological and scientific discourse that ensues. Current genomic-era milestones present a unique opportunity to view scientific advance in a thoughtful light, lacing together discoveries, history, and ethical questions, while encouraging the public to consider the varied facets of this scientific evolution with the same curiosity and enthusiasm as the trailblazers of the Human Genome Project. Consider it an invitation to reflect on the fruits of the genomic era.

PDF

___

Ai J, Wang D, Wei Q, Li H, Gao G (2016). Adeno-associated virus serotype vectors efficiently transduce normal prostate tissue and prostate cancer cells. Eur Urol 69: 179-181.
Anderson WF (2000). Gene therapy. The best of times, the worst of times. Science 288: 627-629.
Austin CP (2004). The impact of the completed human genome sequence on the development of novel therapeutics for human disease. Annu Rev Med 55: 1-13.
Bainbridge JWB, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, Georgiadis A, Mowat FM, Beattie SG, Gardner PJ et al. (2015). Long-term effect of gene therapy on Lebers congenital amaurosis. N Engl J Med 372: 1887-1897.
Baird RD, Caldas C (2013). Genetic heterogeneity in breast cancer: the road to personalized medicine? BMC Med 11: 151.
Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M et al. (2015). A prudent path forward for genomic engineering and germline gene modification. Science 348: 36-38.
Barrangou R (2014). Cas9 targeting and the CRISPR revolution. Science 344: 707-708.
Berg P (2006). Origins of the human genome project: why sequence the human genome when 96% of it is junk? Am J Hum Genet 79: 603-605.
Bissonnette L, Bergeron MG (2012). Infectious disease management through point-of-care personalized medicine molecular diagnostic technologies. J Pers Med 2: 50-70.
Browman G, Hébert PC, Coutts J, Stanbrook MB (2011). Personalized medicine: a windfall for science, but what about patients? Can Med Assoc J 183.
Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, Dickman MJ, Makarova KS, Koonin EV, van der Oost J (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321: 960-964.
Cavazanna-Calvo M, Fischer A (2007). Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 117: 1456-1465.
Celniker SE, Dillon LA, Gerstein MB, Gunsalus KC, Henikoff S, Karpen GH, Kellis M, Lai EC, Lieb JD, MacAlpine DM et al. (2009). Unlocking the secrets of the genome. Nature 459: 927- 930.
Chan IS, Ginsburg GS (2011). Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 12: 217-244. Chin L, Andersen JN, Futreal PA (2011). Cancer genomics: from discovery science to personalized medicine. Nature Med 17: 297-303.
Collins FS, McKusick VA (2001). Implications of the human genome project for medical science. JAMA 285: 540-544.
Collins FS, Morgan M, Patrinos A (2003). The human genome project: lessons from large-scale biology. Science 300: 286-290.
Collins FS, Patrinos A, Jordan E, Chakravarti A, Gesteland R, Walters L (1998). New goals for the U.S. human genome project: 1998- 2003. Science 282: 682-689.
Cooper GM. The complexity of eukaryotic genomes. In: The Cell: A Molecular Approach. 2nd ed. Sunderland, MA, USA: Sinauer Associates, 2000, chap. 4.
Cyranoski D (2016). CRISPR Gene-editing tested in a person. Nature 539: 479.
Davis BD (1992). Fervors, fears and manageable realities. Science 257: 981-982.
Daya S, Berns KI (2008). Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21: 583-593.
Deakin CT, Alexander IE, Kerridge I (2009). Accepting risk in clinical research: is the gene therapy field becoming too riskaverse? Mol Ther 17: 1842-1848.
De Mattos-Arruda L, Rodon J (2013). Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. ONC 18: 1180-1188.
Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J (2010). Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2: 146-158.
Donnelly P (2011). Making sense of the data. Science 331: 1024-1025. Doudna JA, Charpentier E (2014). The new frontier of genome engineering with CRISPR-Cas9. Science 346: 1077.
Douglas JT (2007). Adenoviral vectors for gene therapy. Mol Biotechnol 36: 71-80.
Esvelt KM, Smidler AL, Catteruccia F, Church GM (2014). Concerning RNA-guided gene drives for the alteration of wild populations. eLife 10: 7554/eLife.03401.
Farasat I, Salis HM. (2016). A biophysical model of CRISPR/ Cas9 activity for rational design of genome editing and gene regulation. PLoS Comput Biol 12: doi: 10.1371.
Feero WG, Guttmacher AE (2010). Genomic medicine an updated primer. N Engl J Med 362: 2001-2011.
Fischer A (2000). Severe combined immunodeficiencies (SCID). Clin Exp Immunol 122: 143-149.
Friedmann T, Roblin R (1972). Gene therapy for human genetic disease? Science 175: 949-955.
Gazdar AF (2009). Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 361: 1018-1020. Goodspeed A, Heiser LM, Gray JW, Costello JC (2016). Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res 14: 3-13.
Greenberg AJ, McCormick J, Tapia CJ, Windebank AJ (2011). Translating gene transfer: a stalled effort. Clin Transl Sci 4: 279-281.
Guttmacher AE, Collins FS (2003). Welcome to the genomic era. N Engl J Med 349: 996-998.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
Hamburg MA, Collins FS (2010). The path to personalized medicine. N Engl J Med 363: 301-304.
Horvath P, Barrangou R (2010). CRISPR/Cas, the immune system of bacteria and archaea. Science 327: 167-170.
Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA (2013). RNAguided editing of bacterial genomes using CRISPR-Cas systems. Nature Biotechnol 31: 233-239.
Kaneda Y (2000). Virosomes: evolution of the liposome as a targeted drug delivery system. Adv Drug Deliv Rev 43: 197-205.
Kaufmann KB, Brendel C, Suerth JD, Mueller-Kuller U, ChenWichmann L, Schwäble J, Pahujani S, Kunkel H, Schambach A, Baum C et al. (2013). Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol Ther 21: 648-661.
Kay MA, Glorioso JC, Naldini L (2001). Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature Med 7: 33-40.
Kennedy EM, Kornepathi AVR, Cullen BR (2015). Targeting hepatitis B virus cccDNA using CRISPR/Cas9. Antiviral Res 123: 188-192.
Krupovic M, Koonin EV (2016). Self-synthesizing transposons: unexpected key players in the evolution of viruses and defense systems. Curr Opin Microbiol 31: 25-33.
Lander ES (2011). Initial impact of the sequencing of the human genome. Nature 470: 187-197.
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, Fitzhugh W et al. (2001). Initial sequencing and analysis of the human genome. Nature 409: 860-921.
Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (2015). Dont edit the human germline. Nature 519: 410-411.
Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y et al. (2015). CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6: 363-372.
Liu T, Shen JK, Li Z, Choy E, Hornicek FJ, Duan Z (2016). Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. Cancer Lett 373: 109- 118.
Markert ML, Hutton JJ, Wiginton DA, States JC, Kaufman RE (1988). Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements. J Clin Invest 81: 1323-1327.
Marraffini LA (2015). CRISPR-Cas immunity in prokaryotes. Nature 526: 55-61.
Marshall E (1999). Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245.
Mavilio F (2010). Gene therapy: back on track? EMBO Rep 11: 75.
McEwen JE, Boyer JT, Sun KY, Rothenberg KH, Lockhart NC, Guyer MS (2014). The ethical, legal, and social implications program of the National Human Genome Research Institute: reflections on an ongoing experiment. Annu Rev Genomics Hum Genet 15: 481-505.
Mullard A (2011). Gene therapies advance towards finish line. Nature Rev Drug Discov 10: 719-720.
Munger KM, Gill CJ, Ormond KE, Kirschner KL (2007). The next exclusion debate: assessing technology, ethics, and intellectual disability after the human genome project. Ment Retard Dev Disabil Res Rev 13: 121-128.
Naldini L (2015). Gene therapy returns to centre stage. Nature 526: 351-360.
Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, McIntosh J, Peruta MD, Lheriteau E, Patel N, Raj D et al. (2014). Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371: 1994-2004.
Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX et al. (2016). In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351: 403-407.
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
Offit K (2011). Personalized medicine: new genomics, old lessons. Hum Genet 130: 3-14.
Olopade OI, Grushko TA, Nanda R, Huo D (2008). Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14: 7988-7999.
Pace II JK, Feschotte C (2007). The evolutionary history of human DNA transposons: evidence for intense activity in the primate lineage. Genome Res 17: 422-432.
Reddy EP, Reynolds RK, Santos E, Barbacid M (1982). A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149-152.
Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV et al. (2006). Pharmacogenomics: challenges and opportunities. Ann Intern Med 145: 749-757.
Savulescu J, Pugh J, Douglas T, Gyngell C (2015). The moral imperative to continue gene editing research on human embryos. Protein Cell 6: 476-479.
Shampo MA, Kyle RA (2011). J. Craig Venter The Human Genome Project. Mayo Clin Proc 86: e26-e27.
Sibbald B (2001). Death but one unintended consequence of genetherapy trial. Can Med Assoc J 164: 1612.
Sinkins SP, Gould F (2006). Gene drive systems for insect disease vectors. Nature Rev Genet 7: 427-435.
Suerth JD, Labenski V, Schambach A (2014). Alpharetroviral vectors: From a cancer-causing agent to a useful tool for human gene therapy. Viruses 6: 4811-4838.
Suerth JD, Maetzig T, Brugman MH, Heinz N, Appelt J, Kaufmann KB, Schmidt M, Grez M, Modlich U, Baum C, Schambach A (2012). Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol Ther 20: 1022-1032.
Verma IM, Weitzman MD (2005). Gene therapy: twenty-first century medicine. Annu Rev Biochem 74: 711-738.
Walker RL, Morrissey C (2014). Bioethics methods in the ethical, legal, and social implications of the human genome project literature. Bioethics 28: 481-490.
Walther W, Stein U (2000). Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60: 249- 271.
Wang L, McLeod HL, Weinshilboum RM (2011). Genomics and drug response. N Engl J Med 364: 1144-1153.
Wang T, Wei JJ, Sabatini DM, Lander ES (2014). Genetic screens in human cells using the CRISPR-Cas9 system. Science 343: 80- 84.
Watson JD, Cook-Deegan RM (1991). Origins of the human genome project. FASEB J 5: 8-11.
Wilson RF (2010). The death of Jesse Gelsinger: new evidence of the influence of money and prestige in human research. Am J Law Med 36: 295-325.
Wood JM, Nezworski MT (2005). Science as a history of corrected mistakes: comment. Am Psychol 60: 657-658.
Wu SC, Huang GY, Liu JH (2002). Production of retrovirus and adenovirus vectors for gene therapy: a comparative study using microcarrier and stationary cell culture. Biotechnol Prog 18: 617-622.
Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG (2014). Non-viral vectors for gene-based therapy. Nature Rev Genet 15: 541-555.
Zakim D, Schwab M (2015). Data collection as a barrier to personalized medicine. Trends Pharmacol Sci 36: 68-71.
Zhang C, Yao T, Zheng Y, Li Z, Zhang Q, Zhang L, Zhou D (2015). Development of next generation adeno-associated viral vectors capable of selective tropism and efficient gene delivery. Biomaterials 80: 134-145.
Zhen S, Hua L, Takahashi Y, Narita S, Liu Y, Li Y (2014). In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Commun 450: 1422-1426.